Global Guillain-Barre Syndrome Market Size To Worth USD 1230.51 Million By 2033 | CAGR of 5.99%
Category: HealthcareGlobal Guillain-Barre Syndrome Market Size To Worth USD 1230.51 Million By 2033
According to a research report published by Spherical Insights & Consulting, the Global Guillain-Barre Syndrome Market Size is Expected to Grow from USD 687.72 Million in 2023 to USD 1230.51 Million by 2033, at a CAGR of 5.99% during the forecast period 2023-2033.
Get more details on this report -
Browse key industry insights spread across 288 pages with 110 Market data tables and figures & charts from the report on the "Global Guillain-Bare Syndrome Market Size, Share, and COVID-19 Impact Analysis, By Type (Acute Motor Axonal Neuropathy, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Acute Inflammatory Demyelinating Polyneuropathy, and Miller Fisher Syndrome), By Treatment (Plasma Exchange, Intravenous Immunoglobulin (IVIG), and Others), By Route of Administration (Parenteral and Oral), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033." Get Detailed Report Description Here:https://www.sphericalinsights.com/reports/guillain-barre-syndrome-market
The Guillain-Barre Syndrome (GBS) market is focusing on diagnosing, treating, and managing the rare autoimmune disorder by using therapeutics like intravenous immunoglobulin (IVIG) and plasma exchange (plasmapheresis). GBS is a rare condition where the immune system attacks peripheral nerves, causing numbness, tingling, and muscle weakness. The condition can be sudden and require immediate hospitalization. The market is expected to grow due to rising incidence in infectious disease-prone regions, advancements in diagnostic techniques, and R&D efforts. Healthcare providers are seeking advanced techniques and immunomodulatory therapies, driving market growth. Government initiatives providing financial support to manage GBS have also accelerated the need for treatment. The rising cases of GBS accelerate the need for treatment and promote global awareness of the condition. The market growth is driven by increased awareness of neurological problems, improvements in healthcare, and research into immunotherapy and plasmapheresis procedures. However, a lack of awareness about the GBS and its treatment may impede market growth.
The acute inflammatory demyelinating polyneuropathy segment held the largest share of 55.24% in 2023 and is predicted to grow at a significant CAGR during the predicted period.
Based on the type, the global Guillain-Barre syndrome market is categorized as acute motor axonal neuropathy, chronic inflammatory demyelinating polyradiculoneuropathy, acute inflammatory demyelinating polyneuropathy, and Miller-Fisher syndrome. Among these, the acute inflammatory demyelinating polyneuropathy segment held the largest share of 55.24% in 2023 and is predicted to grow at a significant CAGR during the predicted period. Muscle weakness, greater awareness, and the diagnosis of acute inflammatory demyelinating polyneuropathy are all associated with segmental expansion.
The intravenous immunoglobulin (IVIG) segment accounted for the highest market share of 48.15% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the treatment, the global Guillain-Barre syndrome market is categorized as plasma exchange, intravenous immunoglobulin (IVIG), and others. Among these, the intravenous immunoglobulin (IVIG) segment accounted for the highest market share of 48.15% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment growth is driven by its mild side effects and high sterilization, reduces infection risk, strengthens the immune system, reduces inflammation, aids in autoimmune management, and promotes nerve healing by neutralizing autoantibodies attacking peripheral nerves.
The parenteral segment accounted for the highest market share of 58.41% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the route of administration, the global Guillain-Barre syndrome market is categorized as parenteral and oral. Among these, the parenteral segment accounted for the highest market share of 58.41% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The growth of this segment is attributed to improved bioavailability, targeted drug delivery, widespread usage, increasing healthcare provider demand, reduced gastric irritation, rapid action, patient compliance, and precise dosage.
The hospital pharmacies segment accounted for the highest market share of 50.33% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the distribution channel, the global Guillain-Barre syndrome market is categorized as hospital pharmacies, retail pharmacies, and others. Among these, the hospital pharmacies segment accounted for the highest market share of 50.33% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment's growth is accelerated by offering acute GBS treatments like IVIG therapy and plasmapheresis, addressing the urgent need for effective, personalized, specialized services and medication-dispensing facilities.
North America is expected to hold the greatest share of the global Guillain-Barre syndrome market over the forecast period.
Get more details on this report -
North America is expected to hold the greatest share of the global Guillain-Barre syndrome market over the forecast period. This is attributed to increased awareness, treatment options, and diagnosis rates. The U.S. and Canada are leading the way, with improved healthcare access and online pharmacy adoption. The demand for effective treatments like IVIG and plasma exchange is expected to rise.
Asia Pacific is predicted to hold the fastest-growing region of the global Guillain-Barre syndrome market throughout the estimated period. The Asia Pacific GBS market is experiencing rapid growth, particularly in China, India, Japan, and Australia, driven by increased GBS cases and healthcare infrastructure development. Demand for therapies like IVIG and plasma exchange is increasing, especially for managing severe forms like AIDP and AMAN. Hospital pharmacies play a crucial role in providing these treatments, and increased awareness of GBS-related health risks is driving the market.
Major key players in the global Guillain-Barre syndrome market are Pfizer Inc., CSL Behring LLC, Grifols SA, AbbVie Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Biogen Inc., F. Hoffmann-La Roche Ltd, Merck and Co. Inc., Cadila Healthcare Limited, LGM Pharmaceuticals Inc., Octapharma AG, and others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
- In December 2024, Annexon, Inc. announced positive results from a real-world evidence study supporting ANX005 as a potential treatment for Guillain-Barré Syndrome (GBS). ANX005, the most advanced targeted immunotherapy in development for GBS, is designed to block C1q and complement activity with a single dose to halt disease progression during the critical progressive phase of the disease. This advancement is part of Annexon's late-stage clinical platform of novel therapies for classical complement-mediated neuroinflammatory diseases.
- In December 2024, Hansa Biopharma reported positive results from a Phase 2 study on Imlifidase, a first-in-class IgG-cleaving enzyme, in Guillain-Barré Syndrome (GBS). The study also compared the data to the International Guillain-Barré Syndrome Outcome Study (IGOS), a prospective study by the Inflammatory Neuropathy Consortium. The 15-HMedIdeS-09 study found that severe GBS patients treated with Imlifidase (0.25mg/kg) and IVIg experienced rapid functional improvement, including muscle strength recovery, fast return to independently walking, and a median time to independently walk by 16 days.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global Guillain-Barre syndrome market based on the below-mentioned segments:
Global Guillain-Barre Syndrome Market, By Type
- Acute Motor Axonal Neurotherapy
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Acute Inflammatory Demyelinating Polyneuropathy
- Miller Fisher Syndrome
Global Guillain-Barre Syndrome Market, By Treatment
- Plasma Exchange
- Intravenous Immunoglobulin (IVIG)
- Others
Global Guillain-Barre Syndrome Market, By Route of Administration
- Parenteral
- Oral
Global Guillain-Barre Syndrome Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Global Guillain-Barre Syndrome Market, By Region
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?